AIDSWEEKLY Plus; Monday, November 29, 2004
Staff Medical Writers

"Fosamprenavir, the prodrug formulation of amprenavir, is a protease inhibitor recently approved in the US for the treatment of HIV infection. This agent combines the pharmacological profile of amprenavir with a low pill burden and flexible dosing schedule. Three large international trials have been completed," investigators in the United States report.

"In treatment-naive patients," wrote S. Becker and colleagues, "fosamprenavir, both ritonavir-boosted and -unboosted, met primary end points of non-inferiority against nelfinavir. Among naive patients, no protease inhibitor mutations emerged in those failing the boosted fosamprenavir regimen."

"Boosted fosamprenavir was compared to lopinavir/ritonavir in treatment-experienced patients. Non-inferiority was not achieved," researchers said, "but similar numbers of patients achieved viral suppression when fosamprenavir was dosed twice-daily."

"Fosamprenavir demonstrates a favorable lipid profile in naive patients, and a low incidence of adverse effects. Fosamprenavir, as with lopinavir/ritonavir," the authors continued, "distinguishes itself among other protease inhibitors with its potent activity in those with advanced HIV."

Becker concluded, "Future trials comparing fosamprenavir with current standard regimens will further assist in defining its role in clinical practice."

Becker and colleagues published their study in Expert Opinion on Pharmacotherapy (Fosamprenavir: advancing HIV protease inhibitor treatment options. Expert Opin Pharmacother. 2004 Sep;5(9):1995-2005.

For additional information, contact S. Becker, Pacific Horizon Med Group, 2351 Clay St., Suite 512, San Francisco, CA 94115, USA.

The publisher of the journal Expert Opinion on Pharmacotherapy can be contacted at: Ashley Publications Ltd., Unitec House, 3RD FL, 2 Albert Place, Finchley Central, London N3 1QB, England.

The information in this article comes under the major subject areas of Fosamprenavir, HIV/AIDS, Protease Inhibitor, and Drug Efficacy.

This article was prepared by AIDS Weekly editors from staff and other reports.

Reference

Becker S, Thornton L. "Fosamprenavir: advancing HIV protease inhibitor treatment options", Expert Opin Pharmacother. 2004 Sep;5(9):1995-2005.

PubMED Related articles Search

041129
AW041115

Copyright © 2004 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.